Cellectis (CLLS) Expected to Announce Quarterly Earnings on Tuesday

Cellectis ( NASDAQ:CLLS Get Free Report ) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, August 5th.

Analysts expect the company to announce earnings of ($0.15) per share and revenue of $10.07 million for the quarter.

Cellectis ( NASDAQ:CLLS Get Free Report ) last issued its quarterly earnings results on Monday, May 12th.

The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts consensus estimates of ($0.15) by ($0.03).

The business had revenue of $12.03 million for the quarter, compared to analysts expectations of $12.71 million.

Cellectis had a negative return on equity of 62.55% and a negative net margin of 114.82%.

On average, analysts expect Cellectis to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cellectis Stock Performance Shares of CLLS stock opened at $2.85 on Tuesday.

The company has a market capitalization of $158.40 million, a P/E ratio of -3.31 and a beta of 2.91.

The businesss 50 day moving average is $1.62 and its two-hundred day moving average is $1.50.

The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.44.

Cellectis has a 12-month low of $1.10 and a 12-month high of $3.05.

Hedge Funds Weigh In On Cellectis Analysts Set New Price Targets Several research firms have recently weighed in on CLLS.

Barclays decreased their target price on Cellectis from $5.00 to $4.00 and set an overweight rating on the stock in a research report on Tuesday, May 13th.

Wall Street Zen downgraded Cellectis from a hold rating to a sell rating in a research report on Thursday, May 22nd.

Check Out Our Latest Research Report on CLLS About Cellectis ( Get Free Report ) Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.

The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Recommended Stories Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter ..

This article has been shared from the original article on baseballnewssource, here is the link to the original article.